Cell-Penetrating Antibody Complexes for Non-Viral Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery technologies, such as viral vectors and synthetic liposomes, face limitations including complexity of production, limited packaging capacity, and unfavorable immunological features, hindering effective in vivo gene therapy applications.
Innovation Solution
Compositions comprising monoclonal antibodies or their cell-penetrating fragments, like 3E10, are used to non-covalently link with nucleic acid cargo, enabling efficient delivery into cells by forming complexes that can be encapsulated in nanoparticles for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for nucleic acid delivery, then delivery efficiency is improved, but production complexity and immunological risks increase
Solution Approach 1:
The patent uses cell-penetrating antibodies as intermediary carriers to deliver nucleic acids into cells. These antibodies naturally penetrate cell membranes and can be conjugated to nucleic acid cargo, serving as a mediator that avoids the complexity of viral vector production while maintaining delivery efficiency. The antibody-nucleic acid conjugate system provides a non-viral alternative that simplifies production protocols.
Solution Approach 2:
The patent modifies the parameters of the delivery system by using recombinant antibody technology to create cell-penetrating antibodies with specific properties. By changing the antibody isotype, conjugation chemistry, and cargo attachment methods, the system achieves efficient delivery without the immunogenicity and production complexity associated with viral vectors.
2Productivity
If viral vectors are used for nucleic acid delivery, then delivery efficiency is improved, but immunological safety deteriorates
Solution Approach 1:
The patent employs non-viral antibody-based carriers that are biodegradable and transient, replacing persistent viral vectors. These antibody-nucleic acid conjugates are naturally cleared by the body after delivering their cargo, reducing long-term immunological risks while maintaining effective delivery. The disposable nature of these carriers eliminates concerns about viral integration and persistent immune activation.
Solution Approach 2:
The patent converts the natural immune clearance mechanism, which is typically a hurdle for nucleic acid delivery, into a benefit by using antibodies that are naturally designed to be immunogenic yet controllable. The Fc region of the antibodies can be engineered to modulate immune responses, turning potential harmful immunogenicity into a controllable feature that enhances delivery while minimizing adverse immune reactions.
3Productivity
If conventional liposome delivery is used, then nucleic acid delivery is achieved, but cellular uptake efficiency decreases
Solution Approach 1:
The patent creates composite delivery systems by conjugating cell-penetrating antibodies to nucleic acid cargo. This composite structure combines the protective and delivery capabilities of antibodies with the therapeutic function of nucleic acids, achieving superior cellular uptake compared to conventional liposomes. The antibody component provides active targeting and membrane penetration capabilities that enhance cellular internalization.
Solution Approach 2:
The patent segments the delivery function from the therapeutic cargo by using separate antibody components that can be independently optimized for cell penetration. This segmentation allows the antibody to specialize in cellular uptake while the nucleic acid cargo maintains its therapeutic function, resulting in more efficient delivery compared to all-in-one liposome systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the uptake and accumulation of nucleic acids in cells, offering a non-viral, efficient, and targeted delivery system for therapeutic nucleic acids, including siRNA and mRNA, with potential applications in gene therapy and CAR T cell therapy.
Implementation Method 1
a monoclonal antibody, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody... wherein (a) and (b) are non-covalently linked
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.